Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

October 23, 2018

Study Completion Date

November 12, 2018

Conditions
PruritusPsoriasis
Interventions
DRUG

5 mg Serlopitant Tablets

Serlopitant Tablets

DRUG

Matching Placebo Tablets

Placebo Tablets

Trial Locations (39)

10023

Study Site 500, New York

11375

Study Site 375, Forest Hills

19008

Study Site 211, Broomall

23220

Study Site 336, Richmond

23502

Study Site 217, Norfolk

32771

Study Site 206, Sanford

33134

Study Site 210, Coral Gables

33144

Study Site 331, Miami

33162

Study Site 222, North Miami Beach

33165

Study Site 348, Miami

33761

Study Site 212, Clearwater

37130

Study Site 205, Murfreesboro

40202

Study Site 228, Louisville

40241

Study Site 216, Louisville

43209

Study Site 516, Bexley

46617

Study Site 207, South Bend

47150

Study Site 360, New Albany

48038

Study Site 219, Clinton Township

48103

Study Site 506, Ann Arbor

55432

Study Site 209, Fridley

64506

Study Site 371, Saint Joseph

68144

Study Site 227, Omaha

72022

Study Site 221, Bryant

75024

Study Site 339, Plano

77004

Study Site 224, Houston

77479

Study Site 223, Sugar Land

77598

Study Site 226, Webster

77845

Study Site 182, College Station

78218

Study Site 203, San Antonio

78660

Study Site 359, Pflugerville

83704

Study Site 213, Boise

90212

Study Site 220, Beverly Hills

90404

Study Site 376, Santa Monica

92108

Study Site 356, San Diego

92123

Study Site 202, San Diego

Study Site 215, San Diego

94538

Study Site 204, Fremont

08520

Study Site 201, East Windsor

02919

Study Site 345, Johnston

All Listed Sponsors
lead

Vyne Therapeutics Inc.

INDUSTRY

NCT03343639 - Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis | Biotech Hunter | Biotech Hunter